Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia
<p>Glioblastoma (GBM) remains a cancer of high unmet clinical need. Current standard of care for GBM, consisting of maximal surgical resection, followed by ionisation radiation (IR) plus concomitant and adjuvant temozolomide (TMZ), provides less than 15-month survival benefit. Efforts by conve...
Autores principales: | Johanssen, T, McVeigh, L, Erridge, S, Higgins, G, Straehla, J, Frame, M, Aittokallio, T, Carragher, NO, Ebner, D |
---|---|
Formato: | Journal article |
Publicado: |
Frontiers Media
2023
|
Ejemplares similares
-
A chemogenomic HTS for combinatorial drug discovery in glioblastoma
por: Johanssen, T, et al.
Publicado: (2022) -
Where are all the surgeons in clinical academia?
por: McVeigh, J, et al.
Publicado: (2022) -
Recent advances in the therapeutic strategies of glioblastoma multiforme
por: Aldoghachi, Asraa Faris, et al.
Publicado: (2022) -
Accelerating glioblastoma therapeutics via venture philanthropy
por: Siah, Kien Wei, et al.
Publicado: (2022) -
The violinist in London's concert life, 1750-1784 : Felice Giardini and his contemporaries
por: McVeigh, S
Publicado: (1979)